Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences : GILD) Presents Phase 3 Clinical Data in HIV-1 at IDWeek 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 08:18am CET

Gilead Sciences, Inc. (NASDAQ:GILD) announced detailed 48-week results from a Phase 3 study (Study 1878) evaluating the efficacy and safety of switching virologically suppressed HIV-1 infected adult patients from a multi-tablet regimen containing a boosted protease inhibitor (bPI) to a fixed-dose combination of bictegravir (50 mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF), a dual-NRTI backbone. In the ongoing study, BIC/FTC/TAF was found to be statistically non-inferior to regimens containing bPIs and demonstrated no treatment-emergent resistance at 48 weeks. The data are being presented at IDWeek 2017 in San Diego (Session 228).

These data demonstrate the potential of BIC/FTC/TAF to match the efficacy of a boosted protease inhibitor regimen while also offering a high barrier to resistance and fewer interactions with other drugs, said Eric Daar, MD, Chief of the Division of HIV Medicine at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and lead author of Study 1878. The findings, along with data from three other Phase 3 studies in both treatment-experienced and treatment-nave patients, suggest that the investigational regimen of BIC/FTC/TAF may be appropriate for a broad range of people living with HIV.

In Study 1878, a total of 577 virologically suppressed adults with HIV taking regimens of boosted atazanavir (ATV) or darunavir (DRV) + abacavir/lamivudine (ABC/3TC) or FTC/tenofovir disoproxil fumarate (TDF) were randomized 1:1 to continue their bPI regimen or to switch to open-label coformulated BIC/FTC/TAF once daily. At the primary endpoint of Week 48, switching to BIC/FTC/TAF was non-inferior to continuing on a bPI regimen with 1.7 percent of patients in each group having HIV-1 RNA =50 c/mL (difference: 0.0 percent, 95 percent CI: -2.5 percent to 2.5 percent, p=1.00); the proportion of patients with HIV-1 RNA

(c) 2003-2017 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
02/24GILEAD SCIENCES : Fish & Richardson Wipes Out $2.5 Billion Patent Verdict Agains..
AQ
02/23GILEAD SCIENCES' : Trademark Application for "SIMPLY POWERFUL" Filed
AQ
02/23GILEAD SCIENCES : An Application for the Trademark "AZLI" Has Been Filed by Gile..
AQ
02/23GILEAD SCIENCES : Trademark Application for "LETAIRIS" Filed by Gilead Sciences
AQ
02/22GILEAD SCIENCES : Announces Senior Management Change
BU
02/22SANGAMO THERAPEUTICS : Surges on Therapy Collaboration Deal with Kite -- Market ..
DJ
02/22Sangamo in $3 billion gene-editing deal with Gilead
RE
02/22GILEAD SCIENCES : Kite, a Gilead Company, And Sangamo Therapeutics Announce Coll..
PR
02/21GILEAD SCIENCES : Wired News - Gilead Sciences Rejoices as Federal Judge Reverse..
AC
02/15GILEAD SCIENCES : New Data from Gilead Sciences Illuminate Findings in Antiretro..
AQ
More news
News from SeekingAlpha
02/23Gilead withdraws application in Europe for expanded use of Zydelig 
02/23YOUR DAILY PHARMA SCOOP : Dynavax Achieves Major Milestone, GW Pharmaceuticals G.. 
02/23SORRENTO THERAPEUTICS : Will This Novel CAR-T Deliver Robust Value? 
02/23U.S. BIOTECH/PHARMA SECTOR DAILY OBS : February 22, 2018 
02/22SANGAMO THERAPEUTICS : Great Start To 2018 - $3 Billion KITE Announcement 
Financials ($)
Sales 2018 21 270 M
EBIT 2018 11 296 M
Net income 2018 6 975 M
Debt 2018 16 887 M
Yield 2018 2,79%
P/E ratio 2018 15,36
P/E ratio 2019 14,46
EV / Sales 2018 5,75x
EV / Sales 2019 5,66x
Capitalization 105 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 88,8 $
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES10.83%105 375
VERTEX PHARMACEUTICALS5.16%39 931
REGENERON PHARMACEUTICALS-16.00%34 113
BIOVERATIV INC93.43%11 243
GENMAB16.62%10 343
BLUEBIRD BIO INC12.97%10 168